Tune is pioneering a new therapeutic modality that can fine-tune any gene network. In breaking free from the limitations of traditional gene and cell therapies, Tune is developing solutions for even the most challenging and intractable diseases – and building the capacity to transform human health and medicine.

Based in Durham, NC. and Seattle, WA., Tune was founded and built around a veteran leadership team with deep expertise in gene and cell therapy, genome editing, and epigenetics.

Learn more about our team of scientists and experts as well as opportunities at the company.
 

Meet the Band

Leadership

Matt Kane

Chief Executive Officer

Read More

Charles Gersbach

Co-Founder, Acting Chief Scientific Officer

Read More

Akira Matsuno

Co-Founder, President, and CFO

Read More

Blythe Sather

Vice President, Head of Research

Read More

Heidi Zhang

Executive Vice President, Head of TechOps

Read More

Nicole Slepsky

Vice President, Human Resources

Read More
Dr. Fyodor Urnov is a Tune Co-Founder and Chair of the Scientific Advisory Board at Tune Therapeutics

Fyodor Urnov

Co-Founder

Read More

Board of Directors

Matt Kane

Chief Executive Officer

Read More

Charles Gersbach

Co-Founder, Acting Chief Scientific Officer

Read More

Ali Behbahani

New Enterprise Associates

Read More

Dan McHugh

Emerson Collective

Read More

Investors

  • New Enterprise Associates , NEA
  • Emerson Collective
  • Hatteras Venture Partners
  • Mission Biocapital
  • Saisai Ventures
  • Alexandria Ventures